|Author(s)/Faculty: Antoni Ribas, MD, PhD; Keith T. Flaherty, MD; Grant A. McArthur, MB, BS, BMedSci PhD, FRACP, FAHMS|
Melanoma is the deadliest form of skin cancer. Historically, treatment options have been limited for patients with advanced disease, and prognosis has been poor. Fortunately, improvements in the genetic and molecular characterization of the disease, advances in development of novel therapeutic agents, and individualization of treatment are leading toward an improvement in the prognosis for this patient population.
Over the past decade, treatment of melanoma has been revolutionized with the development of effective molecular and immune targeted therapies, some of which have received FDA approval. As the field of melanoma management continues to rapidly evolve, it is critical for clinicians to be aware of the clinical advances and effective treatment strategies for the management of this disease.